Modifies provisions relating to limits on selling or purchasing certain drugs
Summary
HB1201 revises Missouri’s laws governing the sale, purchase, dispensing, and tracking of over-the-counter methamphetamine precursor drugs, specifically products containing ephedrine, pseudoephedrine, or phenylpropanolamine. The bill repeals and reenacts sections 195.417 and 579.060 to update quantity limits, pharmacy handling rules, reporting requirements, and criminal penalties tied to these products.
The bill keeps the existing prescription exception for valid prescriptions, but otherwise sets the same core purchase/sale caps over different time periods: no more than 7.2 grams in a 30-day period, no more than 3.6 grams in a 24-hour period, and increases the annual limit from 43 grams to 61.2 grams. It also requires these products to be sold from behind the pharmacy counter by a pharmacist or registered pharmacy technician, requires pharmacies to submit sales information to the state, and adds a manufacturer fee system beginning October 1, 2025 to support the real-time pseudoephedrine tracking system. The bill also preserves and expands enforcement provisions, including inspection access for law enforcement and misdemeanor penalties for knowing or reckless violations.
Impact
HB1201 would amend Missouri’s controlled-substance-adjacent retail drug rules by changing section 195.417 and the related offense provisions in section 579.060. It would raise the annual quantity threshold for precursor-drug purchases and sales, formalize pharmacy-only access and reporting obligations, create a manufacturer fee requirement tied to the state’s real-time electronic pseudoephedrine tracking system, and update criminal liability for violations. It also continues to preempt local ordinances on these products and voids certain local prescription requirements, while preserving exceptions for valid prescriptions and certain animal feed or herbal ephedra products.
Sentiment
Based on the bill text and the absence of recorded committee discussion or votes, the overall sentiment appears neutral and regulatory rather than overtly partisan. The measure is framed as a public-safety and enforcement update aimed at controlling methamphetamine precursor access while maintaining lawful pharmacy access for legitimate consumers. The inclusion of a higher annual limit and a manufacturer fee suggests an attempt to balance retail access, state tracking, and anti-diversion enforcement.
Contention
The main points of potential contention are the bill’s tighter pharmacy-handling and reporting requirements, the new manufacturer fee to fund the tracking system, and the criminal penalties for violations. Retail pharmacies and manufacturers may view the compliance and fee provisions as burdensome, while law enforcement and public-safety advocates may support them as tools to reduce methamphetamine production. Another likely issue is the increase in the annual purchase limit from 43 grams to 61.2 grams, which could be seen either as a practical adjustment for legitimate consumers or as a weakening of diversion controls.